Heparan sulfate (HS) is a linear, polydisperse sulfated polysaccharide belonging to the glycosaminoglycan family. HS proteoglycans are ubiquitously found at the cell surface and extracellular matrix in animal species. HS is involved in the interaction with a wide variety of proteins and the regulation of many biological activities. In certain pathologic conditions, expression and shedding of HS proteoglycans is overregulated, or enzymatic degradation of HS in lysosomes is deficient, both leading to excess circulating free HS chains in blood plasma. HS has therefore been suggested as a biomarker for various severe disease states.
Introduction

HS structure and biological role
Heparan sulfate (HS) is a linear, polydisperse sulfated polysaccharide belonging to the glycosaminoglycan family. It is built of a major repeating disaccharide unit consisting of glucoronic acid and glucosamine (scheme 1) [1, 2] . The glucosamine may be 6-O-sulfated, either N-sulfated or N-acetylated, and sporadically 3-O-sulfated, while the glucuronic acid may be 2-O-sulfated. Typically, the average degree of sulfation is around one per disaccharide. HS proteoglycans are ubiquitously found at the cell surface and extracellular matrix in animal species. HS interacts with a large number of proteins and is involved in the regulation of many biological activities including cell proliferation, inflammation, angiogenesis, viral infectivity and development [3, 4] .
Pathologic elevation of HS plasma levels and HS as potential biomarker
In certain disease states, expression and shedding of HS proteoglycans is overregulated or enzymatic degradation of HS in lysosomes is deficient, both leading to excess circulating free HS chains in blood plasma that may be partially excreted into urine. Thus, elevated HS levels in plasma, serum or urine have been suggested as a biomarker for a variety of disease states, including various types of mucopolysaccharidosis, graft versus host disease (GVHD), dengue infection and septic shock. While normal plasma displays a low HS level in the range 0,1-0,3 µg/mL (as determined by disaccharide analysis, table 1), pathologic HS levels are often multifold enhanced (table 2) .
Biomarkers as measurable indicators of normal biological processes, pathogenic processes or response to a therapeutic intervention, are becoming increasingly important in diagnosis and drug development. Among the large number of potential biomarkers, only few have been approved to date by the US FDA. The availability of reliable quantitation techniques is crucial for the verification and validation of putative biomarkers.
The potential of HS as a biomarker is exemplified by graft versus host disease (GVHD), a life-threatening complication related to transplantation. After hematopoietic stem cell transplantation, serum HS is highly elevated before the onset of clinical symptoms of GVHD, and the HS serum level correlates to the severity of the disease [5] . The early diagnosis and treatment (by serum protease inhibitors) of GVHD has been shown to improve survival. Therefore, elevated serum or plasma HS levels may serve as an early biomarker of acute cellular rejection, and HS level is a relevant parameter for therapy monitoring. Derived from the relative abundance of unsulfated, mono-, di-and trisulfated disaccharides as given in the reference.
Methods for HS quantification in plasma or serum
The structural heterogeneity makes the quantification of heparan sulfate in complex matrices such as human plasma challenging. HS level in human plasma or serum is usually quantified by either disaccharide analysis (DS analysis) or enzyme linked immunosorbent assay (ELISA), see Derived from the relative abundance of unsulfated, mono-, di-and trisulfated disaccharides as given in the reference. eventually a modification step such as fluorophore labelling, and finally the identification and quantification of disaccharides by LC-MS methods or electrophoresis. Earlier protocols [6] have described colorimetric quantification of HS by uronic acid-carbazole reaction, but also require a complex procedure for the extraction and purification of HS from plasma.
The ELISA method is based on two heparan sulfate-specific monoclonal antibodies that target N-acetylated and N-sulfated sites of HS. It is easier to perform than disaccharide analysis and requires "only" a microplate reader as spectroscopic instrumentation. The commonly used ELISA method still requires sample pre-teatment and long incubation times, so that overall assay time HS detection in serum sums up to about 40 hours according to the protocol of the provider [16] . The ELISA assay commonly detects a much higher (by a factor 20-40) HS level in human plasma than the disaccharide assays (table 1). All detections listed in table 1 used a HS ELISA kit from the same manufacturer. A reasonable explanation is therefore that the HS calibrant for construction of the standard curve has a lower number of epitopes than human plasma HS [14] .
In one study, the HS content of 18 urine samples (4 samples of normal donors and 14 samples of MPS and other patients) was analyzed by both methods: Disaccharide analysis and ELISA [12] . The correlation between the two methods was poor, the ELISA/HPLC ratio of detected HS ranged between 0.26 and 15.8, i.e. in some samples, ELISA detects a 4 times lower HS quantity than disaccharide analysis, while in other samples, ELISA detects 16 times more HS than disaccharide analysis. The discrepancy may be related to the structural diversity of HS molecules.
Assuming that normal HS plasma levels are about 0,2 µg/mL as detected by disaccharide analysis (table 1) , a tentative "correction" of the ELISA-determined concentrations, based on the relative increase of HS over controls or normal levels, yields HS plasma levels in the range 1-5 µg/mL for mucopolysaccharidosis, dengue infection, graft versus host disease and septic shock (table 2) .
A convenient and fast method for the quantification of heparan sulfate in human plasma or serum would simplify the detection of HS and advance its use as a biomarker. We describe here as an alternative method for HS detection in human plasma the application of the fluorescent probe "Heparin Red". The latter was initially described as an experimental probe for heparin detection [17] and has meanwhile been developed further into commercially available assays [18] . Heparin Red is a polyamine modified, red-emissive perylene diimide fluorophore (scheme 1, right). It forms a supramolecular aggregate with polysulfated polysaccharides, resulting in contact quenching of fluorescence (scheme 2). The strong binding of the polycationic probe to polyanionic heparin appears to be controlled by both electrostatic and aromatic pi-stacking interactions [19] . In this contribution, we describe for the first time application of Heparin Red to the determination of heparan sulfate in human plasma. This is to our knowledge the first example for the direct detection of HS plasma levels in the low µg/mL range by a mix-and-read optical assay. 
Materials and Methods
Instrumentation
Heparan sulfate
Heparan sulfate from porcine mucosa, highly purified fractions I and III (Cat No GAG-HS I
and GAG-HS III) were purchased from Iduron Ltd, Cheshire, UK. 
Plasma
Heparin Red® Ultra
For determination of low heparan sulfate concentrations in aqueous solution, the protocol of the provider for a 96-well microplate was modified: 90 µL of the heparan sulfate containing sample was pipetted into a microplate well. Then, 90 µL of Heparin Red Ultra solution was added to the samples as simultaneously as possible. For sample numbers > 10, a 12-channel pipette was used for addititon of Heparin Red Ultra solution. The microplate was immediately introduced in the fluorescence reader and mixing was performed using the plate shaking function of the microplate reader (setting "high", 1 minute). Immediately after mixing, fluorescence was recorded within 1 minute. Detections were performed as duplicates.
Spiked plasma samples
Plasma samples containing defined mass concentrations of heparin sulfate were prepared by adding aqueous solutions (10 vol%) of the corresponding heparan sulfate to plasma and vortexing, to achieve a concentration of 100 µg/mL. Heparan sulfate concentrations required for the detections were adjusted by further dilution of this 100 µg/mL stock solution with the same plasma and vortexing. The spiked plasma samples were stored at -20°C for at least one day and up to several months, thawed at room temperature and vortexed before use.
Results and discussion
Detection of heparan sulfate in aqueous samples
All detections have been performed with spiked samples using commercially available, highly purified heparan sulfate fractions (HS I and HS III) from porcine mucosa. The Heparin Red Kit was first applied to the detection of heparan sulfate at different concentrations in aqueous samples, using the protocol of the provider for plasma samples. A higher sensitivity can be achieved when a different commercial assay, Heparin Red Ultra, is applied. This assay is preferable for matrices other than plasma or serum [18, 21] and can be more readily adapted for higher sensitivity. Using a modified protocol, the detection limit for heparan sulfate is about 0,1 µg/mL (figure 2). These results suggest that sensitivities in the sub-µg/mL range can be achieved in less complex matrices using the Heparin Red Ultra better is the linearity of the response also at higher plasma levels, as observed for unfractionated heparin [22] that is expected to form stronger aggregates due to its higher charge density of -1,7 per monosaccharide. The porcine mucosa heparan sulfate fraction HS I has a charge density of -0,88 per monosaccharide (table 3) and is a good model for human plasma heparan sulfate for which charge densities between -0,55 and -1,1 have been reported (table 1 and 2) . Compared with unfractionated heparin [22] , a significantly higher mass concentration of HS I is required to trigger 50% fluorescence quenching. This is interpreted with the higher negative charge density of heparin, and the tendency of Heparin Red to form charge neutral aggregates with the polyanionic target [19] .
Our experimental data confirm the quantification of HS I in the low µg/mL range by Heparin Red, with a detection limit for pooled normal plasma of about 1 µg/mL. Heparin Red has therefore the potential to detect highly elevated HS levels in the range 1-5 µg/mL that may arise in the course of MPS II, GVHD, Dengue infection or septic shock, by a simple mix-andread assay.
Conclusion
Heparan sulfate is a potential biomarker for a variety disease states, but its quantification in complex matrices such as human plasma is challenging. HS levels in plasma are commonly determined by either disaccharide analysis or ELISA; both methods require time-consuming multistep-protocols. The commercially available Heparin Red Kit enables the detection of HS in plasma by a mix-and-read microplate assay within a few minutes. Heparin Red is a fluorescent probe that readily forms a non-fluorescent aggregate with HS and enables direct detection without plasma sample pretreatment. The assay appears to be sufficiently sensitive to detect highly eleveated HS levels in the range 1-5 µg/mL, as reported for mucopolysaccharidosis, graft versus host disease after transplantation, dengue infection or septic shock. The study was performed with spiked plasma samples, and the ability of the assay to detect endogeneous HS in patient samples needs to be confirmed. Our findings mark a significant step toward the development of a convenient and fast method for the quantification of HS in human plasma, with the potential to simplify the detection and advance the acceptance of HS as a biomarker.
